Lilly To Acquire Centessa; Upfront Consideration Represents Equity Value Of Approx. $6.3 Bln

Eli Lilly agreed to acquire all issued and to-be-issued share capital of Centessa for $38.00 in cash per share plus one non-transferrable consideration (definitive agreement). The transaction is a material biotech M&A event likely positive for Centessa equity holders (cash consideration) and relevant to the healthcare sector, though it will likely face customary regulatory review.

Analysis

Eli Lilly agreed to acquire all issued and to-be-issued share capital of Centessa for $38.00 in cash per share plus one non-transferrable consideration (definitive agreement). The transaction is a material biotech M&A event likely positive for Centessa equity holders (cash consideration) and relevant to the healthcare sector, though it will likely face customary regulatory review.